Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. Conflict of Interest: Dr. Warshaw has conducted clinical trials for Novartis, Astellas, Dermik, Clay-Park, Paddock, and Barrier.
Toenail onychomycosis: current and future treatment options
Article first published online: 31 MAR 2007
Volume 20, Issue 1, pages 31–46, January 2007
How to Cite
Finch, J. J. and Warshaw, E. M. (2007), Toenail onychomycosis: current and future treatment options. Dermatologic Therapy, 20: 31–46. doi: 10.1111/j.1529-8019.2007.00109.x
- Issue published online: 31 MAR 2007
- Article first published online: 31 MAR 2007
ABSTRACT: Onychomycosis is a common disease affecting as much as 8% of the general population. Treatment of onychomycosis is challenging, complicated by low cure rates and relatively high relapse rates. This paper reviews the efficacy of current oral, topical, and surgical treatment options. Currently, the treatment of choice for toenail onychomycosis is oral terbinafine because of its high efficacy, low relapse rates, and cost-effectiveness. Oral itraconazole or fluconazole could be considered for infections caused by Candida. Topical therapies may be a useful adjunct to these systemic therapies, but are less effective when used alone. More research is needed to determine the best measures for preventing reinfection.